Aug. 22, 2025 -- ViRx@Stanford, a leading biosecurity and pandemic preparedness initiative, and Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), an innovative AI-driven drug repurposing company, today announced a strategic partnership under the "BE READI!" initiative. This collaboration will leverage Fifty1's advanced AI platform to repurpose existing drugs into potent antiviral therapies, addressing urgent viral threats and enhancing global health security. The partnership posit

Aug. 21, 2025 -- Cube Biotech, a pioneer in membrane protein stabilization and purification, and X-Chem, the global leader in DNA-Encoded Library (DEL) technology and data-driven drug discovery, are proud to announce the successful conclusion of Project DEL-MP. Project DEL-MP was a collaborative initiative demonstrating that copolymer-stabilized membrane proteins are not only suitable for DEL screening, they also open up completely new possibilities for even the most challenging targets. The g

19 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Sales are expected to begin on a named patient basis in Q1 2026, with broader commercial sales anticipated in late 2026 following market authorization

Acquisition Poised to Accelerate Life-Saving Interventions, Combining Academic Excellence with Real-World Innovation to Address Global Addiction Crises and Unlock Multi-Billion Market Opportunities Aug. 19, 2025 --- Branded Legacy, Inc. (OTC: BLEG), a leading diversified holdings company dedicated to pioneering health and wellness solutions, today announced a groundbreaking strategic partnership between its wholly-owned subsidiary, Bio-Legacy Evaluative Group, and McMaster University, one of t

Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V. Starr and Co., Inc., eliminating all senior secured debt from its balance sheet. Entered into an Asset Purchase Agreement with Celeniv Pte. Ltd., or Celeniv, to monetize Celularity intellectual property assets and eliminate senior secured debt. In connection therewith entered into a License Agreement with Celeniv to license back the intellectual property assets on an exc

Aug. 12, 2025 -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced it has received written agreement regarding a registrational trial design from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the Company’s planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR). “Securing a Speci

Acquisition Poised to Drive Substantial Shareholder Value Through Innovative Technologies, Projected Multi-Million Revenues, and Strategic Leadership Alignment: Amin Janmohamed Steps Up as CEO and Dr. Kristian Thorlund as Chairman to Spearhead Long-Term Success Aug. 12, 2025 -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a dynamic diversified holdings company at the forefront of health and wellness innovation, is excited to announce the completion of its game-changing acquisition of Bio Legacy

- Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - Aug. 11, 2025 -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ: TSBX) common sto

FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the potentially eligible patient pool as compared to original study protocol Expanded eligibility criteria now include screening of any hypertensive patients who have received or are scheduled to receive a Medtronic Azure™ or Astra™ pacemaker, including device replacements Aug. 08, 2025 -- Orchestra Bi

Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 patent families. All patents are filed internationally, securing global coverage of buntanetap. Aug. 07, 2025-- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheim